lymphoma

[Frontiers in Immunology] Investigators explored the impact of epigenetic modifiers and differentiation agents on leukemia cell lines of B cell origin, as well as normal B cells.

[Neurochemical Research] Researchers explored the mechanism of hUC-MSC derived exosome's ameliorative effect on the spinal cord injury by combining data from in vivo contusion spinal cord injury model and in vitro cell viability of PC12 cell line stimulated with lipopolysaccharide.

[Blood] The authors showed that late-stage Non-Hodgkin's Lymphoma was resistant to therapy targeting phagocytosis checkpoint CD47, due to the compromised capacity of tumor-associated macrophages to phagocytose lymphoma cells.

[Seagen, Inc.] Seagen, Inc. announced that the Phase III ECHELON-1 clinical trial demonstrated a statistically significant improvement in overall survival in patients with advanced classical Hodgkin lymphoma following treatment with ADCETRIS in combination with chemotherapy.

[Cancer Gene Therapy] Cyclin-dependent kinase 12 (CDK12) activated MYC to repress miR-28-5p/EZH2 and amplified tonic BCR signaling to promote the development of diffuse large B cell lymphoma (DLBCL), which might provide potential therapeutic targets for future therapeutic intervention in DLBCL.

[BeiGene] BeiGene announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental new drug application for BeiGene’s BTK inhibitor BRUKINSA as a treatment for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.